Introduction
Methods
Study Design
Study Population
Study Visits and Treatment
Efficacy Variables
Safety and Tolerability
Statistical Methods
Results
Timolol stratum (TS) | Prostaglandin stratum (PS) | ||||||||
---|---|---|---|---|---|---|---|---|---|
FC (n = 95) | TIM (n = 94) | FC (n = 188) | TAF (n = 187) | ||||||
Gender, n (%) | |||||||||
Male | 44 (46.3) | 36 (38.3) | 70 (37.2) | 61 (32.6) | |||||
Female | 51 (53.7) | 58 (61.7) | 118 (62.8) | 126 (67.4) | |||||
Age (years) | |||||||||
Mean | 64.9 | 67.4 | 65.4 | 65.4 | |||||
SD | 10.3 | 9.2 | 10.7 | 10.3 | |||||
Range | 23–84 | 40–87 | 27–85 | 25–87 | |||||
Central corneal thickness (µm) | Right | Left | Right | Left | Right | Left | Right | Left | |
Mean | 555 | 556 | 554 | 554 | 542 | 541 | 544 | 544 | |
SD | 36.1 | 37.4 | 39.6 | 43.0 | 33.6 | 33.6 | 34.7 | 35.7 | |
Range | 460–659 | 475–665 | 337–640 | 282–631 | 442–646 | 437–635 | 445–648 | 448–637 | |
Ocular diagnosis, worse eye n (%) | |||||||||
Ocular hypertension | 25 (26.3) | 23 (24.5) | 39 (20.7) | 39 (20.9) | |||||
Primary open-angle glaucoma | 69 (72.6) | 69 (73.4) | 140 (74.5) | 139 (74.3) | |||||
Pseudoexfoliative glaucoma | 0 (0.0) | 2 (2.1) | 7 (3.7) | 7 (3.7) | |||||
Pigmentary glaucoma | 1 (1.1) | 0 (0.0) | 2 (1.1) | 2 (1.1) | |||||
Baseline intraocular pressure, mmHg (mean ± SD) ITT dataset | |||||||||
8:00 a.m. | 26.94 (2.84) | 26.55 (2.32) | 26.35 (3.16) | 26.59 (3.21) | |||||
10:00 a.m. | 26.50 (2.33) | 26.32 (2.28) | 25.93 (3.22) | 26.10 (3.01) | |||||
4:00 p.m. | 26.32 (2.08) | 25.97 (2.36) | 25.63 (3.17) | 25.59 (3.13) | |||||
8:00 p.m. | 26.19 (2.30) | 25.87 (2.64) | 25.54 (3.17) | 25.61 (2.74) |
Efficacy in Prior Timolol Users (TS)
RM ANCOVA ITT dataset (month 3) | PF FC versus monotherapy PF TIM (primary with outlier) | PF FC versus monotherapy PF TIM (without outlier) | PF FC versus monotherapy PF TAF |
---|---|---|---|
Difference (mmHg) | −0.885 | −1.136 | −1.516 |
Upper 95% CI | −0.024 | −0.379 | −0.988 |
Lower 95% CI | −1.745 | −1.897 | −2.044 |
p value | 0.044 | 0.004 | <0.001 |
Efficacy in Prior PGA users (PS)
Ocular and Non-ocular Adverse Events
Ocular adverse events | TIM stratum (TS) | PGA stratum (PS) | ||
---|---|---|---|---|
FC (n = 95) | TIM (n = 94) | FC (n = 188) | TAF (n = 187) | |
Conjunctival hyperemiaa
| 4 | 0 | 5 | 3 |
Dry eye | 2 | 1 | 0 | 3 |
Eye irritation | 2 | 3 | 5 | 0 |
Eye pain | 2 | 2 | 7 | 6 |
Eye pruritus | 4 | 0 | 6 | 3 |
Eyelid edema | 0 | 0 | 0 | 4 |
Foreign body sensation | 3 | 0 | 3 | 2 |
Ocular discomfort | 2 | 0 | 0 | 0 |
Ocular hyperemiaa
| 5 | 0 | 4 | 3 |
Vision blurred | 2 | 1 | 3 | 4 |
Eyelid erythema | 0 | 0 | 1 | 2 |
Eyelash growth | 0 | 0 | 2 | 2 |
Eyelash discolouration | 0 | 0 | 1 | 1 |
Eyelash thickening | 0 | 0 | 1 | 1 |
Photophobia | 0 | 0 | 1 | 1 |